Last reviewed · How we verify
DE-117 Ophthalmic Solution QD — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
DE-117 Ophthalmic Solution QD (DE-117 Ophthalmic Solution QD) — Santen Inc.. DE-117 is a selective EP2 receptor agonist that lowers intraocular pressure through increased uveoscleral outflow.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DE-117 Ophthalmic Solution QD TARGET | DE-117 Ophthalmic Solution QD | Santen Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DE-117 Ophthalmic Solution QD CI watch — RSS
- DE-117 Ophthalmic Solution QD CI watch — Atom
- DE-117 Ophthalmic Solution QD CI watch — JSON
- DE-117 Ophthalmic Solution QD alone — RSS
Cite this brief
Drug Landscape (2026). DE-117 Ophthalmic Solution QD — Competitive Intelligence Brief. https://druglandscape.com/ci/de-117-ophthalmic-solution-qd. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing